Jun 28, 2018 Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial Learn More
Jun 7, 2018 Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131 Learn More
Jun 6, 2018 FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma Learn More
May 11, 2018 Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results Learn More